EP4054567A4 - Treating liver disorders - Google Patents

Treating liver disorders Download PDF

Info

Publication number
EP4054567A4
EP4054567A4 EP20886094.0A EP20886094A EP4054567A4 EP 4054567 A4 EP4054567 A4 EP 4054567A4 EP 20886094 A EP20886094 A EP 20886094A EP 4054567 A4 EP4054567 A4 EP 4054567A4
Authority
EP
European Patent Office
Prior art keywords
treating liver
liver disorders
disorders
treating
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20886094.0A
Other languages
German (de)
French (fr)
Other versions
EP4054567A1 (en
Inventor
Martijn Fenaux
Yujin Wang
Weidong Zhong
Kevin Klucher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terns Pharmaceuticals Inc
Original Assignee
Terns Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Pharmaceuticals Inc filed Critical Terns Pharmaceuticals Inc
Publication of EP4054567A1 publication Critical patent/EP4054567A1/en
Publication of EP4054567A4 publication Critical patent/EP4054567A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP20886094.0A 2019-11-08 2020-11-06 Treating liver disorders Pending EP4054567A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962933277P 2019-11-08 2019-11-08
US202063004403P 2020-04-02 2020-04-02
PCT/US2020/059522 WO2021092474A1 (en) 2019-11-08 2020-11-06 Treating liver disorders

Publications (2)

Publication Number Publication Date
EP4054567A1 EP4054567A1 (en) 2022-09-14
EP4054567A4 true EP4054567A4 (en) 2024-01-10

Family

ID=75849579

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20886094.0A Pending EP4054567A4 (en) 2019-11-08 2020-11-06 Treating liver disorders

Country Status (11)

Country Link
EP (1) EP4054567A4 (en)
JP (1) JP2023501386A (en)
KR (1) KR20220098168A (en)
CN (1) CN114667142A (en)
AU (1) AU2020380968A1 (en)
BR (1) BR112022008639A2 (en)
CA (1) CA3160445A1 (en)
CL (1) CL2022001167A1 (en)
IL (1) IL292459A (en)
MX (1) MX2022005407A (en)
WO (1) WO2021092474A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220184114A1 (en) 2020-12-14 2022-06-16 Regeneron Pharmaceuticals, Inc. Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023245A1 (en) * 2017-07-25 2019-01-31 Cedars-Sinai Medical Center Methods for treating liver diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200906823A (en) * 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US20140187633A1 (en) * 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
CA3019496A1 (en) * 2016-03-28 2017-10-05 Intercept Pharmaceuticals, Inc. Medicine obtained by combining fxr agonist and arb
WO2018170173A1 (en) * 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
KR20210052507A (en) * 2018-08-30 2021-05-10 테른스 파마슈티칼스, 인크. Liver disorder treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019023245A1 (en) * 2017-07-25 2019-01-31 Cedars-Sinai Medical Center Methods for treating liver diseases

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"Bile Acids and Their Receptors", vol. 256, 14 June 2019, SPRINGER INTERNATIONAL PUBLISHING, Cham, ISBN: 978-3-030-22005-1, article GEGE CHRISTIAN ET AL: "Nonsteroidal FXR Ligands: Current Status and Clinical Applications", pages: 167 - 205, XP093103470, DOI: 10.1007/164_2019_232 *
ANONYMOUS: "Terns Pharmaceuticals to Present Positive Preclinical Data on FXR Agonist TERN-101 at The Liver Meeting 2019 | Business Wire", 15 October 2019 (2019-10-15), pages 1 - 2, XP093103551, Retrieved from the Internet <URL:https://www.businesswire.com/news/home/20191015005032/en/Terns-Pharmaceuticals-to-Present-Positive-Preclinical-Data-on-FXR-Agonist-TERN-101-at-The-Liver-Meeting -2019> [retrieved on 20231120] *
CARR ROTONYA M ET AL: "FXR Agonists as Therapeutic Agents for Non-alcoholic Fatty Liver Disease", CURRENT ATHEROSCLEROSIS REPORTS, SPRINGER US, NEW YORK, vol. 17, no. 4, 18 February 2015 (2015-02-18), pages 1 - 14, XP035470130, ISSN: 1523-3804, [retrieved on 20150218], DOI: 10.1007/S11883-015-0500-2 *
GENIN MICHAEL J. ET AL: "Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1 H -indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia", JOURNAL OF MEDICINAL CHEMISTRY, vol. 58, no. 24, 14 November 2015 (2015-11-14), US, pages 9768 - 9772, XP055932709, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.5b01161 *
KLUCHER KEVIN ET AL: "FRI-313-A novel farnesoid X receptor agonist, TERN-101, reduces liver steatosis, inflammation, ballooning and fibrosis in a murine model of non-alcoholic steatohepatitis", JOURNAL OF HEPATOLOGY, vol. 70, no. 1, 1 April 2019 (2019-04-01), AMSTERDAM, NL, pages e534, XP093103535, ISSN: 0168-8278, DOI: 10.1016/S0618-8278(19)31056-4 *
See also references of WO2021092474A1 *
YUJIN WANG ET AL: "Pharmacokinetics, Tissue Distribution and Pharmacodynamics of TERN-101, a Novel Farnesoid Xreceptor (FXR) Agonist, in Preclinical Species", HEPATOLOGY; AASLD ABSTRACTS, JOHN WILEY & SONS, INC, US, vol. 70, no. Suppl. 1, 1 October 2019 (2019-10-01), pages 1277, XP009550030, ISSN: 0270-9139 *

Also Published As

Publication number Publication date
MX2022005407A (en) 2022-05-24
WO2021092474A1 (en) 2021-05-14
JP2023501386A (en) 2023-01-18
CL2022001167A1 (en) 2023-02-10
KR20220098168A (en) 2022-07-11
EP4054567A1 (en) 2022-09-14
BR112022008639A2 (en) 2022-07-19
IL292459A (en) 2022-06-01
CA3160445A1 (en) 2021-05-14
AU2020380968A1 (en) 2022-05-12
CN114667142A (en) 2022-06-24

Similar Documents

Publication Publication Date Title
EP3746135A4 (en) Methods and compounds for treating disorders
EP3867745A4 (en) Hyperpiler
EP3833739A4 (en) Akkermansia muciniphila
EP3890748A4 (en) Compositions and methods for the treatment of liver disorders
EP3781482A4 (en) Nano-satellite
EP3692023A4 (en) Benzothiazol compounds and methods using the same for treating neurodegenerative disorders
EP3844156A4 (en) Treating liver disorders
EP3658139A4 (en) Methods for treating liver diseases
EP3973047A4 (en) Methods and compositions for treating liver disorders
EP3893883A4 (en) Methods for the treatment of depression
EP3902536A4 (en) Compositions and methods for treating neurodegenerative disorders
EP3976107A4 (en) Sonosensitization
EP3773491A4 (en) Methods for treating apoe4/4-associated disorders
EP3793566A4 (en) Compositions and methods for reducing spliceopathy and treating rna dominance disorders
EP3752161A4 (en) Methods for treating fibrosis
EP3952851A4 (en) Compounds and methods for treating inflammatory disorders
EP3934632A4 (en) Esketamine for the treatment of depression
EP3954368A4 (en) Compound for treating neurodegenerative disorders
EP4054567A4 (en) Treating liver disorders
EP4003420A4 (en) Il-38-specific antiobodies
EP3755352A4 (en) Methods and compositions for treating movement disorders
EP3972606A4 (en) Treating chronic liver disease
EP3962492A4 (en) Methods for treating neurodegenerative disorders
EP4045046A4 (en) Methods and compositions for treating iron disorders
AU2019900181A0 (en) Treatment

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220511

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20231212

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 413/12 20060101ALI20231206BHEP

Ipc: C07D 261/08 20060101ALI20231206BHEP

Ipc: A61K 31/4545 20060101ALI20231206BHEP

Ipc: A61K 31/42 20060101AFI20231206BHEP